An Open Label, Single Arm, Multicenter Phase II Study of BYL719 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Who Failed to Respond to Platinum-based Therapy.

Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02145312
• Other study ID #: 4-2014-0147
• Status: Recruiting
• Phase: Phase 2
• Start date: October 1, 2016
• Est. completion date: May 2019

Study information

• Verified date: July 2018
• Source: Yonsei University
• Contact: Byung Chul Cho
• Phone: +82 (2) 2228-0880
• Email: CBC1971[@]yuhs.ac
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

One promising approach to the treatment of cancer is inhibition or modulating the crucial signal transduction pathway of PI3K-Akt-mTOR. Several PI3K inhibitors are being tested in the clinical trials for cancer treatment but not for the head and neck cancer yet. BYL719 is an alpha specific I PI3K inhibitor. It showed significant, concentration dependent cell growth inhibition and induction of apoptosis. We suggest multicenter single arm phase II study to determine anti-tumor effects of BYL719 in patients with recurrent and/or metastatic SCCHN who failed to prior chemotherapy regimens. Enrollment will be done in 5 or more clinical trial centers in Korea. Primary objective is to evaluate disease control rate (DCR) at 8 weeks of BYL719, and the efficacy will be evaluated by the investigators analysis based on RECIST version 1.1.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 43
• Est. completion date: May 2019
• Est. primary completion date: May 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histologically or cytologically confirmed recurrent or metastatic squamous-cell carcinoma of head and neck (SCCHN), except nasopharyngeal carcinoma

2. 18 years of age or older

3. Patients must have progressive disease after one or two prior chemotherapy regimens including platinum-based chemotherapy given for the treatment of recurrent and/or metastatic disease, or within 6 months after concurrent chemoradiation (with or without induction chemotherapy) given as a definitive treatment.

4. Life expectancy of at least 12 weeks

5. Ineligibility for local therapy (surgery or radiation for curative intent)

6. At least one lesion that is measurable according to the RECIST 1.1 criteria by CT or MRI

7. ECOG performance score of 0-2

8. Availability of tissue samples (archival tissue or rebiopsied tissues) for molecular analysis (representative paraffin block or unstained sections from tumor diagnostic specimen are mandatory)

9. Adequate organ function and laboratory parameters as defined by:

• Absolute neutrophil count (ANC) =1.5x109/L

• Hemoglobin (Hgb) = 9 g/dl (which may be reached by transfusion)

• Platelets (PLT) = 100 x 109/L (which may be reached by transfusion)

• AST/SCOT and ALT/SGPT = 2.5xULN (upper limit of normal) or = 5 x ULN if liver metastases are present

• Serum bilirubin = 1.5 x ULN

• Serum creatinib = 1.5 x ULN or calculated or directly measured CrCl = 50% LLN (lower limit of normal)

• Fasting plasma glucose (FPG) < 140 mg/dL/7.8mmol/L

Exclusion Criteria:

1. Prior treatment with PI3K pathway inhibitors

2. Nasopharyngeal carcinoma

3. Uncontrolled, untreated brain metastasis. Patients with treated/controlled and asymptomatic CNS metastases may participate in this trial. The patient must have completed any prior treatment for CNS metastases = 28 days (must include radiotherapy and/or surgery) and, if on corticosteroid therapy, should be receiving a stable low dose (e.g. dexamethasone 4 mg or equivalent dose of another corticosteroid for at least 14 days before start of study treatment).

4. Surgery, chemotherapy or irradiation within 3 weeks of study entry

5. Concomitant chemotherapy, hormonal therapy or immunotherapy

6. Clinically significant cardiac disease or impaired cardiac function, such as:

• Congestive heart failure (CHF) requiring treatment (New Yort Heart Association (NYHA) Grade = 2), left ventricular ejection fraction (LVEF) < 50% as determined by multi-gated acquisition (MUGA) scan or echocardiogram (ECHO), or uncontrolled arterial hypertension defined by blood pressure > 140/100 mmHg at rest (average of 3 consecutive readings)

• History or current evidence of clinically significant cardiac arrhythmias, arterial fibrillation and/or conduction abnormality, e.g. congenical long QT syndrome, high grade/complete AV-blockage

• Acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass graft (CABG), coronary angioplasty, or stenting), < 3 months prior to screening

• QT interval adjusted according to Fredericia (QTcF) > 480 msec on screening ECG

7. Patients with diabetes mellitus requiring insulin treatment and/or with clinical signs or with FPG = 140 mg/dL/7.8mmol/L, or history of documented steroid-induced diabetes mellitus.

8. Patient who cannot take the oral drug

9. Impaired GI function or GI disease that may significantly alter the absorption of oral BYL719 (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)

10. Patients who are currently receiving medication with a known risk of prolonging the QT interval or inducing Torsades de Pointes (TdP) and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug treatment.

11. Previous or concomitant malignant disease, except adequately treated basal cell cancer of the skin or cervical cancer in situ, superficial bladder tumors (Ta, Tis & T1) or any cancer curatively treated > 3 years prior study entry

12. Pregnant woman, Breast-feeding woman

13. Other severe acute or chronic medical condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the patient inappropriate for entry into this trial (infection/inflammation, intestinal obstruction, social/psychological complications).

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Head and Neck Neoplasms
• Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Intervention

Drug:
• BYL719
BYL719 is an oral class I a-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds.

Locations

Country	Name	City	State
Korea, Republic of	Yonsei Cancer Center at Yonsei University Medical Center	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Yonsei University

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease control rate	The primary objective of this study is to evaluate disease control rate (DCR) at 8 weeks of BYL719 administered as therapy for patient with recurrent/metastatic head and neck squamous cell carcinoma, comparing with historical control. Efficacy evaluation will be based on RECIST version 1.1. DCR will be expressed percent and 95% confidence interval.	8 weeks of BYL 719 administered as therapy
Secondary	Overall Response Rate (ORR)		24 months
Secondary	Progression-free survival (PFS)		24 months
Secondary	Overall survival (OS)		24 months
Secondary	Time to progression (TPP)		24 months
Secondary	Drug toxicity and safety analysis		24 months
Secondary	Quality of life assessment		24 months